| Literature DB >> 29567093 |
Giulia Donvito1, Fabiana Piscitelli2, Pretal Muldoon1, Asti Jackson1, Rosa Maria Vitale2, Enrico D'Aniello3, Catia Giordano4, Bogna M Ignatowska-Jankowska1, Mohammed A Mustafa1, Francesca Guida4, Gavin N Petrie5, Linda Parker5, Reem Smoum6, Laura Sim-Selley1, Sabatino Maione4, Aron H Lichtman7, M Imad Damaj8, Vincenzo Di Marzo9, Raphael Mechoulam6.
Abstract
Cigarette smokers with brain damage involving the insular cortex display cessation of tobacco smoking, suggesting that this region may contribute to nicotine addiction. In the present study, we speculated that molecules in the insular cortex that are sensitive to experimental traumatic brain injury (TBI) in mice might provide leads to ameliorate nicotine addiction. Using targeted lipidomics, we found that TBI elicited substantial increases of a largely uncharacterized lipid, N-acyl-glycine, N-oleoyl-glycine (OlGly), in the insular cortex of mice. We then evaluated whether intraperitoneal administration of OlGly would alter withdrawal responses in nicotine-dependent mice as well as the rewarding effects of nicotine, as assessed in the conditioned place preference paradigm (CPP). Systemic administration of OlGly reduced mecamylamine-precipitated withdrawal responses in nicotine-dependent mice and prevented nicotine CPP. However, OlGly did not affect morphine CPP, demonstrating a degree of selectivity. Our respective in vitro and in vivo observations that OlGly activated peroxisome proliferator-activated receptor alpha (PPAR-α) and the PPAR-α antagonist GW6471 prevented the OlGly-induced reduction of nicotine CPP in mice suggests that this lipid acts as a functional PPAR-α agonist to attenuate nicotine reward. These findings raise the possibility that the long chain fatty acid amide OlGly may possess efficacy in treating nicotine addiction.Entities:
Keywords: Cannabinoid receptor-1 (CB1); Conditioned place preference (CPP); Insular cortex; N-oleoyl glycine; Nicotine withdrawal; Peroxisome proliferator-activated receptor alpha (PPAR-α)
Mesh:
Substances:
Year: 2018 PMID: 29567093 PMCID: PMC6408981 DOI: 10.1016/j.neuropharm.2018.03.020
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250